Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open-label, Single Sequence, Two-Period Crossover Trial to Evaluate the Effect of Tepotinib on CYP3A by Investigating the PK of the CYP3A Substrate Midazolam in Healthy Subjects

NCT03628339 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.

NCT NCT03628339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03628339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open-label, Single Sequence, Two-Period Crossover Trial to Evaluate the Effect of Tepotinib on CYP3A by Investigating the PK of the CYP3A Substrate Midazolam in Healthy Subjects
Lead sponsor
Merck KGaA, Darmstadt, Germany
Phase
Phase 1
Overall status
Completed
Start date
August 20, 2018
Completion date
October 30, 2018
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy